Post-transcriptional and translational controls mediated by microRNAs (miRNA) regulate diverse biological processes and disease. We systematically dissected regulatory effects of miRNAs relevant to megakaryocytopoiesis and platelet biology by analyzing expression patterns in 79 subjects with thrombocytosis and healthy controls, and integrated these data with transcriptomic and proteomic platforms. We identified and validated a unique 21-miRNA genetic fingerprint associated with thrombocytosis, and demonstrated that a discrete 3-member subset effectively defines ET phenotypes. The genetic signature includes functional guide and passenger strands of the previously-uncharacterized miR 490 (5p and 3p), both of which displayed restricted, low-level expression in megakaryocytes/platelets (compared to leukocytes), and aberrant expression during thrombocytosis, most profound in essential thrombocythemia (ET).
Introduction
Recent data have demonstrated that both megakaryocytes and platelets retain an abundant and diverse array of microRNAs (miRNAs). Largely studied within the context of mammalian development and lineage specification, miRNAs are a class of non-coding 21-to 24-bp species that primarily regulate protein translation by post-transcriptional targeting of 3'-UTRs [reviewed 1 ]. Emerging evidence has implicated miRNAs in the control of megakaryocytopoiesis 2 and in progenitor fate during the megakaryocyte-erythroid transition, 3 presumably by modulating expression of key transcriptional regulators. 2, 3 Furthermore, distinct patterns of miRNA expression have been seen in differentiated hematopoietic cells 4 and in subsets of patients with myeloproliferative neoplasms, 5, 6 further implicating discrete miRNAs in lineage commitment during normal or dysregulated hematopoiesis.
Anucleate platelets retain megakaryocyte-derived mRNAs, 7 and have evolved unique adaptive signals for maintenance of genetic and protein diversity. 8, 9 Quiescent platelets generally display minimal translational activity, although maximally-activated platelets retain the capacity for protein synthesis, with implications for modulating arthritis-associated inflammation, 10 or the production of platelet progeny in vivo. 11 Interestingly, platelets also retain a competent miRNA pathway capable of converting precursor miRNAs through functional Dicer/Argonaute 2 (Ago2) complexes, 12 with evidence that Ago2-miRNA-223 complexes specifically regulate expression of the functionally-important platelet purinergic P2Y 12 adenosine-diphosphate (ADP) receptor. Additional evidence suggests that miRNAs (miR 28) can modulate expression of the c-mpl thrombopoietin (Tpo) platelet receptor 5 and that miR 96-mediated regulation of endobrevin/VAMP8 (vesicle-associated membrane protein 8) affects human platelet functional responsiveness. 13 The potential importance of a functionally competent miRNA pathway is further highlighted by the enrichment of platelet miRNAs compared to other hematopoietic cells such as granulocytes and megakaryocytes. 12 We have previously shown that distinct platelet phenotypes can be genetically classified using a restricted set of mRNA biomarkers. 14 We have now expanded these observations to further investigate the impact of miRNAs in thrombocytosis, and have identified a unique fingerprint associated with enhanced megakaryocytopoiesis and/or proplatelet formation.
Systematic analyses of miRNA with transcriptomic and proteomic studies using an integrated computational framework identified miR 490 5p and its putative target dishevelled associated
For personal use only. on April 20, 2017 . by guest www.bloodjournal.org From activator of morphogenesis 1 (DAAM1) as reciprocally-regulated pairs in thrombocythemic platelets, presumably by translational control and not by mRNA target degradation. These data suggest a unique mechanism for modifying the platelet proteome in times of exaggerated platelet production.
Materials and Methods
Human Subjects. A total of 79 platelet RNAs were randomly chosen from a SUNY at Stony Brook institutional review board approved study of thrombocytosis subjects and healthy controls; 14 samples were assigned to 3 cohorts based on previous phenotypic characterization:
ET (N = 27), RT (N = 22) and healthy controls (N = 30) [patient characteristics are provided in Table S1 ]. Leukocytes were isolated by density-gradient centrifugation from sodium citratetreated blood (0.4% v/v final concentration) while platelet-rich plasma (PRP) served as the source of platelet mRNA. Leukocyte contamination of PRP was < 1×10 -5 , and the isolation, quantification and quality control of both leukocyte and platelet RNAs was established using an Agilent 2100 Bioanalyzer as previously described. 14 JAK2V 617 F mutation genotyping (exon 12,
1849
G→T transversion) was completed on all subjects. 15 This study was conducted in accordance with the Declaration of Helsinki.
MicroRNA Profiling and Data Analysis. Platelet RNA (100 ng/sample) was labeled with Cy3 amine reactive dyes using a miRNA labeling kit (Ambion), and samples were hybridized to an Agilent G4470C human microRNA gene chip that incorporates 866 human and 89 viral microRNAs (miRBase database version 12.0). Images were acquired using a GenePix 4000B scanner, followed by quantification and processing using Agilent Feature Extraction Software (version 10.7). Within group coefficient of variation (CV) was determined to evaluate intraarray reproducibility, and samples with values below the default (CV <15%) were re-arrayed until they fulfilled the acceptable requirement. The Microarray data was. Microarray data were analyzed using Bioconductor package on R (version 2.11) and deposited in the public GEO database (GEO accession number GSE39046). A moderate filtering step was adopted to specifically include miRNAs with >70% present calls in any of the 3 groups (ET, Normal and RT), followed by quantile normalization with K-nearest neighbor (KNN) imputation (K=10) for A comprehensive discriminant analysis was used to identify an initial biomarker subset that separated class on the basis of microarray data, restricted to 2 -4 miRNAs to prevent overfitting. The fidelity of the genetic biomarker subsets as class prediction tools for both microarray and Q-PCR was established using linear discriminant analysis (LDA) with a leave-one-out crossvalidation analysis. 17 The posterior classification probability for each subject was derived and the binary decision for group assignment was based on individual highest probability; the same biomarker set using the microarray data was applied to the Q-PCR data. control. Platelet DAAM1 mRNA was quantified using 125 ng RNA and fluorescence-based SYBR green 1 standardized to β-actin (oligonucleotide primers are available in Table S2 ).
Quantitative real time PCR (Q-PCR
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For personal use only. on April 20, 2017 . by guest www.bloodjournal.org From Hematopoietic assays and lentiviral transduction. Lentiviruses expressing miR 490 (LV 490) or empty virus control (LV 000) driven by the elongation factor 1 α (EF1α) promoter and containing the puromycin resistant cassette were obtained from Biosettia (San Diego, CA).
VSV-G (vesicular stomatitis virus) pseudotyped lentiviruses were generated in 293T cells and concentrated stocks were titered in NIH-3T3 cells. 18 Transduction efficiencies in 293T cells for both viruses were nearly identical with infectious units (IU) titers as follows: LV000 (1.8 X course and bilineage expansion) were maintained in puromycin-selected cells using SFEM supplemented with CC100 expansion cocktail, 50 ng/mL TPO, and 2 U/mL erythropoietin. Cells were fixed at D7 using 1 % formalin and flow cytometric quantification using FITC-conjugated anti-CD41 MAb (integrin α IIb , Mk marker) or anti-glycophorin A (erythroid) for determination of lineage-specificity; alternatively, cells were pelleted at distinct time points for RNA isolation. Table S2 Platelet mass spectrometric and protein analyses. Platelet-rich plasma from three healthy controls and three ET subjects was incubated with 20 μM acetylsalicylic acid, 0.1 μM prostaglandin E 1 (PGE 1 ), and 13 mM EDTA at 37 0 C for 20 minutes to ensure quiescence, followed by isolation of gel-filtered platelets (GFP) over a Sepharose 2B column as previously RmiR.Hs.miRNA [referred to as our "knowledge base"], followed by (ii) a second ("data-driven base") for comparative integration of mRNA and proteomic data. Microarray mRNA profiles included our previously-described 6 ET subjects and 5 healthy controls (GEO accession number GPL1716); 22 a filtering step was applied to retain genes expressed in at least 6 samples, and genes represented by duplicate probes were combined and averaged prior to quantilenormalization. For proteomics data, quantile-normalized MS spectral counts were averaged by cohort, restricting the analyses to proteins displaying spectral counts >10 to bypass the inherent limitations of protein quantification at low spectral counts. Samples were specifically filtered to identify mRNA/protein pairs with counts present in one group and absent in another, or were analyzed by SAM when expressed in a minimum of 4/6 samples. In the first iteration, an inverse correlation between miRNA/mRNA abundance was built to reflect miRNA-mediated target degradation mechanism, while in the second iteration we applied statistically unchanged mRNA expression levels (group mean folds [GMF] within the range 0.5 < GMF <2.0 with insignificant p-values >0.05). For all statistical algorithms, p-values were corrected by Benjamini-Hochberg multiple testing correction.
Results
Dysregulated miRNA expression patterns among normal and thrombocytotic cohorts
To gain insight into platelet miRNA function and expression patterns in normal and pathological conditions (thrombocytosis), we microarrayed 79 human platelet samples from a previously-described cohort, 14 Absolute platelet miRNA expression patterns ranged from N = 232 (healthy controls) to N = 309 (RT) ( Fig. 1A and Table S3 ). These aggregate data considerably expand upon the previouslydescribed platelet miRNA expression repertoire; 12 more importantly, they establish the dynamic nature of the megakaryocytic/platelet transcriptome during situations of megakaryoctyopoiesis and/or enhanced proplatelet formation.
Identification of differentially-expressed miRNAs
Initial unsupervised hierarchical clustering of 392 aggregate miRNAs revealed an expression pattern that genetically segregated the groups by phenotype (Fig. 1B) . 1C and Table 1 ). Aggregate group-wise comparisons demonstrated less pronounced differences between NO and RT, results that were consistent with the phenotypic co-segregation using unsupervised hierarchical clustering (vide supra). We repeated the unsupervised hierarchical clustering among the three groups using the 21-member miRNAs (Fig. 1D) A subset of 20 of the 21 miRNAs was re-analyzed using Q-PCR as a second platform to validate the microarray expression differences between ET and NO (the pri-miRNA let 7d was excluded). A high correlation coefficient was observed between the two methods in aggregate (r = 0.69, p = 0.02), or individually where 19/20 miRNAs exhibited concordant group medians ( Figs. 2A -2C ). The consistency of miRNA expression profiles using two independent platforms verified the fidelity of the 20 biomarkers and prompted more focused studies.
A discrete 3-miRNA subset discriminates normal from ET platelets
We applied various statistical classifiers to define a limited miRNA subset capable of discriminating normal and thrombocythemic phenotypes. The initial searching algorithm identified 19 distinct combinations of 3 miRNAs demonstrating class prediction accuracy >90%, although repeat analysis using leave-one-out cross validation refined this list to 3 miRNAs (miR 10a, miR 148a, and miR 490 5p). The application of this miRNA subset to both the microarray and Q-PCR data was confirmed using three distinct statistical classifiers (Figs. 
D -E; Table
2), providing both statistical and cross-platform validation. The identical 3 miRNA subset performed less robustly in discriminating RT from NO (Table S4) , and we were unable to define a more robust RT/NO discriminatory subset using the 21-miRNA subset and de novo computational algorithms. This is entirely consistent with the previously-identified limited differences between RT and NO miRNA profiles.
miR 490 displays lineage (Mk/platelet)-restricted expression and is aberrantly-expressed during thrombocytosis
The abundance and lineage-specificity of the microRNAs was established by simultaneously comparing expression patterns in leukocytes and platelets (both normal and thrombocytosis) (Fig. 3) . Only miR 490 (both 5p and 3p) demonstrated relative lineagespecificity with low-level leukocyte expression that was minimally 50-fold less than any of the other miRNAs studied (except for miR 34b); consistent with previous observations miR 150 displayed the highest leukocyte expression. 25 Among the 21-member miRNA list, miR 490 demonstrated the lowest expression in normal platelets, displaying ~10-fold less abundance than other miRNAs. Comparative sequence alignments of miR 490 demonstrated stringent sequence homology across mammalian species (Fig. S1) , evolutionarily conserved in critical seed regions known to be important for assembly of the RNA-inducing silencing complex (RISC). 26 Given its lineage-focused expression and evolutionarily-conserved sequence --coupled with lack of genetic/functional information on miR 490 --we specifically studied its expression patterns using ex vivo expanded CD34 + hematopoietic stem cells in a bilineage model of megakaryocyteerythroid progenitor (MEP) lineage specification. 3 As shown (Fig. 4A) , both miR 490 5p and miR 490 3p demonstrated coordinate low-level expression beyond D7, patterns that contrasted sharply with the megakaryocyte-erythrocyte progenitor marker miR 150 3 whose expression was readily evident at D6 and generally >2-logs higher throughout the 21-day time course.
Furthermore, miR 490 abundance at D21 was remarkably similar to that found in normal subjects (refer to Fig. 3A and 4B, below) . These studies were entirely consistent with the presence of low-level miR 490 abundance in normal platelets, and aberrant expression restricted to states of exaggerated Mk expansion and/or proplatelet formation.
For (Fig. 4B) . Furthermore, the level of miR 490 expression using LV 490 was not dissimilar to that of miR 150 which was used as a standard to assess expression levels of a physiologically-relevant Mk miRNA. 
D). Given the interrelatedness between the vertebrate erythroid and Mk developmental
repertoire, 3 we applied the bilineage cell culture system to quantify effects on Mk/erythroid lineage specification. As assessed using flow cytometry for GlyA (erythroid) or CD41 (Mk) expression 7 days post transduction, we saw no evidence that miR 490 shifted the Mk/erythroid progenitor balance (Fig. 4E) . Thus, although miR 490 displayed lineage-restrictions and ectopic expression associated with the thrombocytotic phenotype, these collective data demonstrate that its expression is not sufficient for enhanced Mk expansion or lineage-specification during hematopoiesis.
miR 490 target identification using integrated datasets
We developed a heuristic algorithm to identify putative miR 490 targets whose expression could be modulated during thrombocytosis. Given the limitations of miRNA target identification using computational databases, 27 we systematically dissected the effects of dysregulated miRNA 490 expressions by incorporating a workflow model linking miRNA, mRNA, and proteomic expression patterns in normal and thrombocytotic states (Fig. 5A) . We used previouslydescribed mRNA genetic profiles from 6 ET patients and 5 healthy controls, 22 and spectral (peptide) counts generated by multidimensional protein identification technology (MudPIT) 20 as a semi-quantitative means of platelet protein estimation, using samples from three healthy . translation repression) . Using the two-step target identification algorithm, we identified 38 mRNAs predicted to be directly repressed by transcriptional repression (Table S5) , and 150 mRNAs putatively regulated by translational control (Table S6) . Detailed integration of the protein profiles with these mRNA/miRNA candidates narrowed the candidate target list from 188 genes (none of which were represented in the degradation pathway) to a single mRNA/protein pair identified as DAAM1 (dishevelled-associated activator of morphogenesis 1).
Furthermore, DAAM1 expression appeared as a putative target restricted to translation repression (i.e. diminished ET protein expression unrelated to platelet DAAM1 mRNA levels).
DAAM1 characterization in normal and thrombocythemic platelets
The formin DAAM1 is required for directional cell migration and polarity during development, regulatory effects acting indirectly or directly via nucleating properties of actin 28 Limited information is available for platelet DAAM1, although recent data suggest that it functions as an activation-dependent intermediary linking Rho GTPase to actin assembly; 29 furthermore, its inhibitory effects on dishevelled may modulate non-canonical Wnt signaling pathways in platelets. 28, 30 We confirmed DAAM1 target identification using a reporter construct encompassing the 3'-UTR and synthetic double-stranded RNAs specific for either miR 490 5p or miR 490 3p, thereby providing further dissection of the relative roles of either of the strands in modulating DAAM1 protein expression. As shown in Figs. 5B -5C, inhibition of DAAM1 translation efficiency was restricted to miR 490 5p, with no inhibition using either miR 490 3p or the non-relevant C. elegans miR 239b stem-loop primer. These data are entirely consistent with our work-flow model which specifically identified miR 490 5p as the DAAM1 inhibitory microRNA.
Analysis of DAAM1 mRNA expression patterns in hematopoietic cells using a previously described database established a megakaryocyte-restricted pattern of expression 31 ( Fig. S2) , prompting us to compare expression patterns in ET and normal platelets. As shown in Fig. 6A , DAAM1 mRNA was readily identified (and comparable) in both cohorts with no evidence that diminished ET DAAM1 was explained by decreased mRNA levels; these data
For personal use only. on April 20, 2017 . by guest www.bloodjournal.org From were entirely consistent with and predicted by our computational algorithm. Detailed review of the MS chromatograms confirmed that the DAAM1 spectral counts in ET were 52% of those in normal platelets (Fig. 6B) of normal) (Fig. 6C) . These MS data were entirely consistent with immunoblot analysis, although there was heterogeneity of DAAM1 expression across the cohorts (Fig. 6D) . Given the limiting resolution of immunoblots to quantitative differences at the low dynamic range found in ET, we applied multiple reactions monitoring (MRM) to reliably characterize and quantify DAAM1 peptide abundance free of co-eluting peptides. 21 We specifically tracked the m/z 1215.8 transition to its doubly-charged Y 19 ion from an individual ET and normal platelet sample, specifically quantifying ET DAAM1 abundance ~40% of normal. The specificity of the elution peptide was established by following the m/z 1094.6 transition ( Fig. 6E-F) . Collectively, these studies using immunoblot analysis, DAAM1-specific peptides quantification, and MRM consistently established ET DAAM1 abundance at ~40% of normal platelets.
Discussion
We have identified a unique 21-miRNA signature occurring in the setting of exaggerated platelet production, either associated with the myeloproliferative neoplasm (MPN) ET or selflimiting situations of enhanced platelet production (RT). The majority of the differentiallyexpressed miRNAs displayed congruent directional behavior irrespective of the thrombocytosis etiology, supporting a molecular model whereby normal and exaggerated thrombopoiesis represent genetically-defined continua along a convergent pathway, rather than qualitatively distinct genetic entities. Thus, subjects with ET display the most exaggerated expression patterns while those with RT represent an intermediary subset, collectively defined by quantitatively-distinct expression patterns of the 21-miRNA signature. This concept of quantitative genetics and phenotypic progression is well-exemplified in MPN whereby the "strength" (or allelic burden) of the JAK2V 617 F signal may represent one determinant of the MPN phenotype. 32 Similarly, data using various murine models also support the concept that the level of JAK2V
617
F can initiate and sustain differential MPN phenotypes. 33 Our data reinforce and extend to miRNAs the paradigm that quantitative differences involving the genetic fingerprint may be associated with (or confer) distinct phenotypes, i.e. a self-limiting phenotype seen in RT compared to the sustained phenotype associated with ET.
Given the convergence of c-mpl/Tpo and Jak/Stat pathways in normal and MPNassociated platelet production, it is not unexpected that the 21-miRNA thrombocytosis expression signatures remained concordant, the notable exception being miR 144/144* which was specifically up-regulated in RT and down-regulated in ET. Interestingly, miR 144 is known to be transcribed with miR 451 on a single precursor RNA (pri-miRNA), 24 and both are lineage(erythroid)-enriched in hematopoiesis models using zebrafish (D. rerio). The miR 144/451 locus is a direct GATA1 transcriptional target, although effects on erythropoiesis appear to be restricted to miR 451, with no evidence that either microRNA has an effect on thrombopoiesis. with no prior description of this miRNA in MPN studies, 5, 6, 34 and/or models of hematopoiesis 4, 24 or megakaryocytic differentiation. 2, 35, 36 Given its aberrant expression during thrombocytosis, our data suggest that miR 490 represents a unique biomarker of exaggerated megakaryocytopoiesis and/or proplatelet formation, although its physiological function(s) remain to be precisely We developed an integrated proteomic/genetic approach to identify putative miR 490
targets by studying the ET proteome, and validated the specificity of miR 490 5p/DAAM1
inhibition. What are the implications for diminished DAAM1 expression on platelet and/or megakaryocyte functions in ET? Characteristic features of formins are the forming homology (FH) domains which are essential for mediating linear actin polymerization, functions distinct from proteins such as Arp2/3 which initiate and elongate branched actin filaments. DAAM1 was initially identified as a disheveled interacting protein mediating the Wnt/planar cell polarity pathway, 37 and recent data have established both the functional capacity of platelet DAAM1 in actin assembly, 29 and the relevance of the canonical Wnt signaling pathway as a negative modulator of platelet responsiveness. 30 The latter is especially relevant given known platelet functional abnormalities and thrombohemorrhagic consequences in ET. 14 In contrast, no information is available for DAAM1 function in Mk despite the requisite role of actin-based forces on proplatelet formation. Recent data using Daam1-knockout mice have established a crucial role in heart morphogenesis by regulating filamentous actin assembly and cytoskeletal organization. 38 The associated embryonic lethality precluded detailed analysis of the hematopoietic system, although DAAM1's megakaryocyte-enriched pattern of expression presumably connotes functional properties relevant to megakaryocytopoiesis and/or proplatelet formation.
Further studies are required to establish if miR 490 or DAAM1 have requisite functions in exaggerated thrombopoiesis occurring in the background of MPNs or reactive thrombocytosis.
Given its low-level expression during Mk differentiation, the functional effects of miR 490 inhibition using specific microRNA inhibitors (or other approaches) are best evaluated using in vivo models associated with miR 490 overexpression (such as enhanced platelet formation). We are currently in the process of evaluating and testing murine models of thrombocytosis (along with evaluation of their Mks that presumably will demonstrate altered miR 490 and/or DAAM1 expression) as a comprehensive approach to precisely define these inter-relationships relevant to exaggerated proplatelet formation. Such an approach is especially relevant given the promiscuity of miRNAs for their cognate targets (i.e. one miRNA typically has multiple targets), coupled with the converse regulation of mRNAs by a multiplicity of miRNAs. 1 Similarly, although our data define altered DAAM1 expression in ET platelets, miR 490/DAAM1 functional consequences in RT remain incomplete. In preliminary data using a small RT cohort, we noted that DAAM1 levels appeared comparable to those found in healthy controls (not unexpected given the ~2-fold miR 490 increase in RT), although inter-subject variability precludes definitive comparisons and awaits ongoing, integrated studies as outlined above.
Our integrated work-flow model to identify putative miR 490 targets (both 490 5p and 490 3p) suggests that miR 490 5p-loaded RISC modulates DAAM1 protein expression by suppressing translation independent of an effect on DAAM1 mRNA stability. While the disparate miRNA regulatory pathways (i.e. degradation vs. translation arrest) are welldescribed, 1 a recent study suggests that miRNAs retain dual capacity for enhanced mRNA translation, depending on the proliferative phase of the cell cycle.
39
This physiological switch is controlled by altered protein composition of target mRNA 3'-UTRs, either through stimulatory FXR1 or inhibitory GW12 recruitments to the miRNA/Ago complex. 39, 40 Although the cell cycle is largely irrelevant to functions of circulating platelets, recent data suggest that platelets produce functional progeny which involves a form of cell division not requiring a nucleus. Normalized DAAM1-specific spectral counts from MudPit analyses are expressed as the mean ± SEM from 3 normal and 3 ET subjects. C. DAAM1 peptide abundance was quantified between cohorts for each of two peptides, and expressed as the mean ± SEM (N=3/cohort). D.
Immunoblot analysis was completed using 4-15% SDS-PAGE for each of 6 platelet lysates. E. 
